04.04.26 -- Advancing RNA Newsletter Best Of March

mRNA innovation now hinges as much on manufacturing materials as on molecular design, with novel inputs shaping performance, cost, and scalability. As these less-mature materials move rapidly into production, strategic material selection and supplier alignment are becoming critical to manufacturing resilience and long-term success.

As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. Investors are looking for more than promise, but actionable potential and manufacturability. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.

In episode 2 of mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist, Advancing RNA's ARW sits down with Sophia Lugo and  Michelle Lynn Hall to learn their wish lists for RNA developments for 2026 and their take on an edited quote by Oscar Wilde: “The mRNA industry can survive everything but…?”

The mRNA Technology Transfer Program empowers LMICs with scalable vaccine production through partnerships that drive innovation in mRNA and set a global blueprint for equitable health access.

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

Drug development accelerates with AI, decentralized trials, and adaptive protocols, but legacy CRO infrastructure lags. See how platform-based systems enable speed, quality, and automation.